Replimune Group, Inc.

REPL ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Sep 2026 Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024
Operating Activities
Net Income $-57.1M $-69.8M $-73.2M $-70.9M $-83.1M $-86.7M $-74.1M $-66.3M
Depreciation & Amortization $800.0K $937.0K $859.0K $800.0K $800.0K $873.0K $866.0K $1.0M
Depreciation — — — — — — — —
Amortization — — — — — — — —
Stock-Based Compensation $10.5M $7.7M $8.1M $7.0M $8.3M $8.8M $8.3M $8.6M
Net Cash from Operating Activities $-47.7M $-75.7M $-56.2M $-66.0M $-81.2M $-77.0M $-53.7M $-50.7M
Investing Activities
Capital Expenditures $77.0K $6.0K $5.0K $135.0K $1.3M $2.7M $1.1M $1.8M
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $9.8M $50.0M $86.5M $75.1M $84.2M $65.0M $-7.7M $-46.3M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $160.5M $800.0K $55.7M $10.5M $324.0K $-158.0K $-132.0K $155.9M
Net Change in Cash $122.5M $-23.7M $86.1M $20.7M $4.9M $-13.7M $-61.1M $58.7M
Free Cash Flow $-47.8M $-75.7M $-56.2M $-66.1M $-82.6M $-79.8M $-54.9M $-52.5M
← Newer Page 1 of 5 Older →